Abstract
The medical approach to transgender children and adolescents is outlined by the World Professional Association for Transgender Health and the Endocrine Society. All treatment considerations must be guided by careful assessment for the diagnosis of gender dysphoria by a mental health professional with experience in gender identity and working with youth. Prior to the start of puberty, no medical intervention is required. Medical interventions in pubertal youth are aimed at suppressing the development of the secondary sex characteristics of the natal sex and promoting the development of secondary sex characteristics of the affirmed sex. Suppression of puberty using gonadotropin-releasing hormone agonists can be considered at Tanner stage 2. Initiation of gender-affirming hormones (testosterone or estrogen) has historically been considered at age 16, however, contemporary practice is trending to use patient and family readiness factors as opposed to an age restriction.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Herman JL, Flores AR, Brown TNT, Wilson B. DM, Conron K. Age of individuals who identify as transgender in the United States. The Williams Institute; 2017.
Hsieh S, Leininger J. Resource list: clinical care programs for gender-nonconforming children and adolescents. Pediatr Ann. 2014;43:238–44.
Delemarre-van de Wall HA, Cohen-Kettenis PT. Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects. Eur J Endocrinol. 2006;155:S131–7.
Coleman E, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgenderism. 2012;13:165–232.
Hembree WC, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2017;102:1–35.
Center of Excellence for Transgender Health. Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people. University of California San Fransisco. http://transhealth.ucsf.edu/trans?page=guidelines-home. Accessed 3/19/2018.
Rosenthal SM. Approach to the patient: transgender youth: endocrine considerations. J Clin Endocrinol Metab. 2014;99:4379–89.
Simons L, Leibowitz SF, Hidalgo M. Understanding gender variance in children and adolescents. Pediatr Ann. 2014;43:e126–31.
Shumer DE, Nokoff NJ, Spack NP. Advances in the care of transgender children and adolescents. Adv Pediatr. 2016;63:79–102.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed.; 2013.
Witchel SF, Lee PA. In: Sperling M, editor. A Pediatric endocrinology. Saunders Elsevier; 2008, p. 132.
Hughes, I. A. In: Sperling MA, editor. Pediatric endocrinology. Saunders Elsevier; 2008, p. 676–679.
Rosenfield RL, Cooke DW, Radovick S. In: Sperling MA, editor. Pediatric endocrinology. Saunders Elsevier; 2008, p. 532–559.
Marshal WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;45:13–23.
Marshall W, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44:291–303.
Marcell, A. V. In: Kligman RM, Behrman RE, Jenson HB, Stanton BF, editors. Nelson textbook of pediatrics. Saunders Elsevier; 2007, p. 60–65.
Steensma TD, Biemond R, de Boer F, Cohen-Kettenis PT. Desisting and persisting gender dysphoria after childhood: a qualitative follow-up study. Clin Child Psychol Psychiatry. 2011.
Steensma T, Kreukels B, de Vries A, Cohen-Kettenis P. Gender identity development in adolescence. Horm Behav. 2013;64:288–97.
Cohen-Kettenis PT, Klink D. Adolescents with gender dysphoria. Best Pract Res Clin Endocrinol Metab. 2015;29:485–95.
Cohen-Kettenis PT, Delemarre-van de Wall HA, Gooren LJG. The treatment of adolescent transsexuals: changing insights. J Sex Med. 2008;5:1892–7.
De Vries ALC, et al. Young adult psychological outcome after puberty suppression and gender reassignment. Pediatrics. 2014;134:1–9.
De Vries ALC, Cohen-Kettenis PT. Clinical management of gender dysphoria in children and adolescents: the Dutch approach. J Homosex. 2012;59:301–20.
Nahata L, Quinn GP, Caltabellotta N, Tishelman A. Mental health concerns and insurance denials among transgender adolescents. LGBT Heal. 2017;4:188–193.
Veale J, Watson R, Peter T, Saewyc E. Mental health disparities among canadian transgender youth. J. Adolesc. Heal. 2017;60:44–9.
Spack NP, et al. Children and adolescents with gender identity disorder referred to a pediatric medical center. Pediatrics. 2012;129:418–25.
Boepple PA, et al. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocr Rev. 1986;7:24–33.
Chen M, Fuqua J. Adolescent transgender health: Awareness does not equal resources. Curr Pediatr Rep. 2016;4:186–7.
Lynch MM, Khandheria MM, Meyer WJ. Retrospective study of the management of childhood and adolescent gender identity disorder using medroxyprogesterone acetate. Int. J. Transgenderism. 2015;16:201–8.
Warren M, Mathews J, Morishima A, Vande Wiele R. The effect of medroxyprogesterone acetate on gonadotropin secretion in girls with precocious puberty. Am J Med Sci. 1975;269:375–81.
Shumer DE, Spack NP. Current management of gender identity disorder in childhood and adolescence: guidelines, barriers and areas of controversy. Curr Opin Endocrinol Diabetes Obes. 2013;20:69–73.
Spratt D, et al. Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection: demonstration in female-to-male transgender patients. J Clin Endocrinol Metab2. 2017;102:2349–55.
Asscheman H, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011;164:635–42.
Vlot M, et al. Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents. Bone. 2017;95:11–9.
Klink D, Caris M, Heijboer A, van Trotsenburg M, Rotteveel J. Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria. J Clin Endocrinol Metab. 2015;100:E270–5.
Wierckx K, et al. Reproductive wish in transsexual men. Hum Reprod2. 2012;27:483–7.
Pasquino A, et al. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab. 2008;93:190–5.
Nahata L, Curci M, Quinn G. Exploring fertility preservation intentions among transgender youth. J Adolesc Heal. 2018;62:123–5.
American Academy of Pediatrics Committee on Bioethics. Informed consent, parental permission, and assent in pediatric practice. Pediatrics. 1995:314–317.
Shumer D, Tishelman A. The role of assent in the treatment of transgender adolescents. Int J Transgenderism. https://doi.org/10.1080/15532739.2015.1075929.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Shumer, D.E., Araya, A. (2019). Endocrine Care of Transgender Children and Adolescents. In: Poretsky, L., Hembree, W. (eds) Transgender Medicine. Contemporary Endocrinology. Humana Press, Cham. https://doi.org/10.1007/978-3-030-05683-4_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-05683-4_9
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-030-05682-7
Online ISBN: 978-3-030-05683-4
eBook Packages: MedicineMedicine (R0)